Natural ester-lysolecithines ( Fig. 1 ) are known to exist in small amounts in biological membranes. Twenty years ago, Westphal et al. at the Max-Planck-Institute in Freiburg found that very small amounts of exogenous lysolecithine strongly enhanced the phagocytic activity of pentoned macrophages in vitro and in vivo (1).
Due to the very short half-life of these ester-lysolecith- Westphal (6) synthesized lysolecithine ether analogues ( Fig. 1) for studies of the macrophage stimulating processes. These compounds are very stable against most phospholipid metabolizing enzymes. Surprisingly, these alkyllysophospholipids showed strong direct cytolytic effects on various tumor cells in vitro and in vivo (7, 8) .
Testing of the structure activity relationship among a variety of synthetic alkyllysophosphocholines showed that a long alkyl chain and a phosphocholine moiety may represent the minimal structural requirement for sufficient antineoplastic effects of the ether lipid analogues (9-1 1). This finding led to the synthesis of a new compound group, the alkylphosphocholines ( Fig. 1) (12, 13) .
In the following report, some preclinical and the first clinical investigations are presented with hexadecylphosphocholine (He-PC).
Material and Methods
Hexadecylphosphocholine was prepared according to the general procedures for the conversion of alcohols into the respective phosphocholines as described by Eibl & Woolley (14) , and Eibl & Westphal(4 In organ distribution studies female NMRI mice (25 to 30 g weight) were used. For this purpose 0.07 MBq He-PC (specific activity: 1.85 MBq/pmoIA) was injected into the tail vein; oral applications with 0.19 MBq He-PC (specific activity: 0.37 MBqlpmoVI) were performed via a tube into the stomach. After the indicated time intervals the animals were killed, the organs removed, weighed, and the amount of radioactivity was determined as described earlier (17). To evaluate the uptake of He-PC in the various organs, the radioactivity was calculated as percentage of total dose per gram organ.
To investigate metabolism of He-PC in the liver, female NMRI mice were injected with 1.85 MBq/pmoVI He-PC (specific activity: 3.9 MBqpmoIA) into the tail vein. The animals were killed after 24 or 72 h respectively. The livers were removed and homogenized. Radioactive metabolites were determined by thin layer chromatography as described before (17, 18).
The first clinical studies on the topical treatment of skin metastases with hexadecylphosphocholine were performed. For better skin penetration He-PC was dissolved at a concentration of 20 mg/ml in a composition of water and alkylglycerols with different alkyl chain lengths (KASKADE, see Table 1 ). Patients with local recurrence of mammary carcinomas were included in the pilot study after their written consent. All patients had a history of exhaustive treatment including chemotherapy and local irradiation. Treatment was performed twice daily on the affected skin areas. In order to detect systemic side effects, blood and urine analyses, ECG and roentgenologic controls were performed. 0.61.2 g.
Results and Discussion
Alkylphosphocholines, a new group of antineoplastic agents, are derived from cytotoxic alkyllysophosphocholines (12, 13). In vitro investigations of He-PC, a compound representative of alkylphosphocholines revealed concentration dependant cytotoxicity and growth inhibition shown in Fig. 2 lines, such as 1-0-octadecyl-2-0-methyl-rac-glycero-3-phosphocholine (OM-GPC) in earlier experiments (19) . The in vivo antitumoral effect of He-PC was studied in DMBA-induced rat mammary carcinomas in comparison to cyclophosphamide, which is known to be an active compound in this tumor model (20). He-PC was given He-PC treatment was well tolerated and no overt toxic symptoms were noted; in particular no weight loss could be observed in the animals. Recently, high therapeutic activity of He-PC was also reported for the methylnitrosourea-induced rat mammary carcinomas, whereas 2 transplantable mammary carcinomas and authochthonous benzopyrene-induced sarcomas in the rat exhibited lowgrade sensitivity to He-PC (21). It is noteworthy that in contrast to most cytostatics, He-PC treatment did not result in any suppression of the white blood count (Fig. 4) .
The leukocyte count, expressed as percentage of normal values, remained unchanged up to a dose of 14.7 mglkg per day when given orally, whereas the highly effective dose of 46.4 m a g per day showed a surprising increase in leukocyte count during the treatment period. After finishing the treatment, the leukocyte count decreased to normal values within one week. Since bone marrow examination did not show augmentation of granulocyte precursor cells (22), it seems likely that an activation of the marginal leukocyte pool in the periphery may be responsible for this increase in leukocyte count.
Biodistribution studies after oral administration of He-PC in mice clearly demonstrated high absorption rates from the intestine (17), permitting oral administration in treatment regimens. This finding is in line with other reports showing that OM-GPC (23) and l-hexadecylmercapto-2-methoxyrnethyl-rac-glycero-3-phosphocholine (24) are well absorbed from the intestinal tract. As is also known for OM-GPC (231, the highest accumulation of He-PC was found to occur in liver, kidney and lungs ( Table 3) . W. DAMENZ, E. A. M. FLEER, D . 1. KIM, A. BREISER, P. HILGARD, J Metabolism of He-PC was investigated in the mouse liver. After oral administration of hexadecylphospho [3H-methyllcholine, a time dependant formation of radiolabelled choline, phosphocholine and 1,2-diacylglycerophosphocholine was observed (Fig. 5) , which suggests the importance of phospholipases C and D in He-PC catabolism. Studies on hydrolysis of He-PC in vitro, carried out with phospholipase C (bacillus cereus) and phospholipase D (partially purified from cabbage) support the finding that He-PC is a substrate for these enzymes (9,ll). Formation of 1,2-diacylglycerophosphocholine, labelled in the polar head group, is consistent with earlier results obtained with 18) . In the latter study it was shown that the labelled phosphocholine group was transferred from OM-GPC into 1,2-diacylglycerol, which resulted in the formation of phosphatidylcholine. The favorable results obtained on tumor response in chemically induced autochthonous rat mammary carcinomas prompted us to investigate the antitumoral effect of He-PC in the topical treatment of skin metastases in humans. For this purpose He-PC was dissolved in short chain alkylglycerols (Table l) , since it was recently demonstrated that these compounds are able to increase drug penetration through biological membranes (25, 26) . Hence, it is possible that these compounds also improve penetration of He-PC into the deeper compartments of the skin. In addition, hexyl-and nonylglycerol display considerable growth inhibition properties on leukemia cells in vitro (to be published).
C. UNGER,
In the clinical pilot study 14 patients with local recurrence of breast carcinoma were included and treated twice daily by topical application. The treatment was well tolerated and apart from minor side effects, such as reddening, flaking and itching, no systemic toxicity was observed. Two patients showed a complete remission lasting 4 and 6 months, and one patient showed a partial remission for 7 months. Skin biopsies taken from invaded and normal skin after treatment revealed a moderate increase in the formation of collagen fibers without affecting the normal skin architecture.
Therefore, topically applied ether lipids may represent a safe and effective treatment of skin metastases. Based on these promising observations, regular phase I trial studies (oral and topical applications) have been started.
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